IMAGE

Fig. 2

ID
ZDB-IMAGE-090710-69
Genes
Antibodies
Source
Figures for Aanstad et al., 2009
Image
Figure Caption

Fig. 2 The Extracellular Domain of Smo Is Required for High-Level Signaling

(A–L) Purmorphamine treatment of WT and smos294 mutant embryos. DMSO-treated WT (A, E, and I), DMSO-treated smos294 mutant (C, G, and K), purmorphamine-treated WT (B, F, and J), and purmorphamine-treated smos294 mutant (D, H, and L) embryos at 24 hpf are shown. Purmorphamine treatment did not significantly affect morphology (B) and caused only a modest increase in Prox1 (green) and sMHC staining (red) (F) but strongly induced ectopic Engrailed (Eng)-positive muscle pioneer cells (MPs) in WT embryos (J). Purmorphamine treatment of smos294 mutants resulted in significant rescue of the morphological phenotype (D) and restored Prox1 (green) and sMHC (red) expression (H), but not Eng expression (L).

(M–T) Injection of SmoΔCRD mRNA in WT and smohi1640 mutant embryos. Prox1 (green) and sMHC (red) staining (M–P) and Eng staining (Q–T) are shown. Injection of 250 pg SmoΔCRD mRNA caused a complete rescue of Prox1 and sMHC expression in smohi1640 mutants (P) compared to uninjected mutants (O) and a slight increase in Prox1 and sMHC expression in WT (N) compared to control (M). In contrast, injection of SmoΔCRD mRNA had no effect on Eng expression in WT (R) compared to control (Q) and did not rescue Eng expression in smohi1640 mutants (T). For quantification, see Tables S1 and S2.

Figure Data
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Curr. Biol.